SI
ESPR

Sofinnova Investments’s Esperion Therapeutics ESPR Stock Holding History

Sofinnova Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,599
Closed -$1.62M – 65
2018
Q3 		$1.62M Sell
36,599
-114,562
-76% -$5.26M 0.14% 54
2018
Q2 		$5.92M Buy
+151,161
New +$7.64M 0.67% 30

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sofinnova Investments's ESPR Position: Q4 2018 in Review

Sofinnova Investments sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 36,599 shares — an estimated $1.62M sold.

Sofinnova Investments first reported a position in ESPR in Q2 2018 and held it in 2 quarters. The position peaked at $5.92M in Q2 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • Sofinnova Investments reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sofinnova Investments sold 36,599 Esperion Therapeutics shares in Q4 2018, an estimated $1.62M.
  • Sofinnova Investments first reported a position in Esperion Therapeutics in Q2 2018 and held it in 2 quarters.
  • Sofinnova Investments's Esperion Therapeutics position peaked at $5.92M in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.